Press Release

HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics Conference

June 08, 2021

Back to list

HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics Conference

June 08, 2021

HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics (AET)Conference  (June 8-10, 2021). This antibody is a potential therapeutic option for patients with CLDN18.2+ gastric cancer.

 

Poster presentation details are highlighted below

 

 

 

About Harbour BioMed


 
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.


 
The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.  

 

For more information, please visit www.harbourbiomed.com

Media and Investor Contact:

Harbio BioMed Public Relations

Phone: +86-21-53399123

E-mail: pr@harbourbiomed.com